In May 2014 the broker acted as lead manger in Admedus’s most recent share placement and clearly has a favourable view of the biotech business.
And my guess is that they are managing the [more than highly likely] upcoming capital raising, so no surprises that they have put a cheery report out on it.
News: Admedus receives A$0.22 price target from Morgans, page-93
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |